Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -102.41% is 68% above its 5-year average of -319.76%, near the high end of its 5-year range (-797.17%–37.95%).
60.67% above its 12-month average of -260.37%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -303.77%.
OPERATING MARGIN
-102.41%
OPERATING MARGIN AVG TTM
-260.37%
OPERATING MARGIN AVG 3Y
-285.53%
OPERATING MARGIN AVG 5Y
-319.76%
OPERATING MARGIN AVG 10Y
-225.43%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+60.67%
CURRENT VS 3Y AVG
+64.13%
CURRENT VS 5Y AVG
+67.97%
CURRENT VS 10Y AVG
+54.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Sutro Biopharma, Inc.
Market Cap
$141.87M
Operating Margin
-102.41%
TTM Avg
-260.37%
3Y Avg
-285.53%
5Y Avg
-319.76%
Market Cap
$142.96M
Operating Margin
-111.00%
TTM Avg
-151.19%
3Y Avg
-184.89%
5Y Avg
-203.40%
Market Cap
$143.10M
Operating Margin
-827.76%
TTM Avg
-1064.28%
3Y Avg
-1054.91%
5Y Avg
-3927.73%
Market Cap
$140.46M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-4081.44%
5Y Avg
-3115.66%
Market Cap
$143.51M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$144.33M
Operating Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-1665.90%
5Y Avg
-1977.59%
Market Cap
$138.93M
Operating Margin
-221.72%
TTM Avg
-110.86%
3Y Avg
-55.43%
5Y Avg
-36.95%
Market Cap
$137.57M
Operating Margin
-3.66%
TTM Avg
-13.20%
3Y Avg
-25.26%
5Y Avg
-22.69%
Market Cap
$137.40M
Operating Margin
-410.23%
TTM Avg
-412.58%
3Y Avg
-412.58%
5Y Avg
-412.58%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $141.87M | -102.41% | -260.37% | -285.53% | -319.76% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.96M | -111.00% | -151.19% | -184.89% | -203.40% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -827.76% | -1064.28% | -1054.91% | -3927.73% |
| Immuneering Corporation (IMRX)vs › | $140.46M | 0.00% | 0.00% | -4081.44% | -3115.66% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.33M | -239.78% | -210.59% | -1665.90% | -1977.59% |
| Alpha Cognition Inc (ACOG)vs › | $138.93M | -221.72% | -110.86% | -55.43% | -36.95% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | -3.66% | -13.20% | -25.26% | -22.69% |
| Atrium Therapeutics, Inc. (RNA)vs › | $137.40M | -410.23% | -412.58% | -412.58% | -412.58% |
| Organigram Global Inc. (OGI)vs › | $136.58M | -34.07% | -27.91% | -72.83% | -67.42% |
Gross Margin
97.2%
Operating Margin
-102.4%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -303.77% |
| 2026-03-31 | -203.91% |
| 2025-12-31 | -288.98% |
| 2025-09-30 | -499.94% |
| 2025-06-30 | -5.25% |
| 2025-03-31 | -393.78% |
| 2024-12-31 | -440.66% |
| 2024-09-30 | -797.17% |
| 2024-06-30 | -189.39% |
| 2024-03-31 | -435.05% |
| 2023-12-31 | 37.95% |
| 2023-09-30 | -260.07% |
| 2023-06-30 | -443.52% |
| 2023-03-31 | -333.26% |
| 2022-12-31 | -570.23% |
| 2022-09-30 | -84.34% |
| 2022-06-30 | -68.97% |
| 2022-03-31 | -663.59% |
| 2021-12-31 | -328.85% |
| 2021-09-30 | -407.12% |
| 2021-06-30 | -34.96% |
| 2021-03-31 | -129.67% |
| 2020-12-31 | -300.11% |
| 2020-09-30 | -59.57% |
| 2020-06-30 | -173.38% |
| 2020-03-31 | -268.18% |
| 2019-12-31 | -130.76% |
| 2019-09-30 | -103.73% |
| 2019-06-30 | -130.02% |
| 2019-03-31 | -165.33% |
| 2018-12-31 | -17.16% |
| 2018-09-30 | -129.62% |
| 2018-06-30 | -211.92% |
| 2018-03-31 | -202.02% |
| 2017-12-31 | -375.45% |
| 2017-09-30 | -6.09% |
| 2017-06-30 | -10.06% |
| 2017-03-31 | -10.06% |
